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Underlying etiology contributes to the outcome of patients after ischemic stroke. In general, patients with ischemic 
stroke of cardioembolic origin have worse functional out-
comes,1,2 higher recurrence rates, and a higher risk of death 
than patients with ischemic stroke of other origin. However, 
little is known on the impact of stroke etiology on functional 
outcome of patients with stroke who underwent endovascular 
treatment (EVT).3
Background and Purpose—Due to chronic hypoperfusion, cervical atherosclerosis may promote cerebral collateral 
circulation. We hypothesized that patients with ischemic stroke due to cervical carotid atherosclerosis have a more 
extensive collateral circulation and better outcomes than patients with cardioembolism. We tested this hypothesis in a 
population of patients who underwent endovascular treatment for large vessel occlusion.
Methods—From the MR-CLEAN Registry (Multicenter Randomized Controlled Trial of Endovascular Treatment for Acute 
Ischemic Stroke in the Netherlands), we selected consecutive adult endovascular treatment patients (March 2014 to June 
2016) with acute ischemic stroke due to anterior circulation large vessel occlusion and compared patients with cervical 
carotid artery stenosis >50% to those with cardioembolic etiology. The primary outcome was collateral score, graded 
on a 4-point scale. Secondary outcomes included the modified Rankin Scale (mRS) score and mortality at 90 days. We 
performed multivariable regression analyses and adjusted for potential confounders.
Results—Of 1627 patients in the Registry, 190 patients with cervical carotid atherosclerosis and 476 with cardioembolism 
were included. Patients with cervical carotid atherosclerosis were younger (median 69 versus 76 years, P<0.001), more 
often male (67% versus 47%, P<0.001), more often had an internal carotid artery terminus occlusion (33% versus 18%, 
P<0.001), and a lower prestroke mRS (mRS score, 0–2; 96% versus 85%, P<0.001), than patients with cardioembolism. 
Stroke due to cervical carotid atherosclerosis was associated with higher collateral score (adjusted common odds ratio, 
1.67 [95% CI, 1.17–2.39]) and lower median mRS at 90 days (adjusted common odds ratio, 1.45 [95% CI, 1.03–2.05]) 
compared with cardioembolic stroke. There was no statistically significant difference in proportion of mRS 0–2 (aOR, 
1.36 [95% CI, 0.90–2.07]) or mortality at 90 days (aOR, 0.80 [95% CI, 0.48–1.34]).
Conclusions—Patients with stroke due to cervical carotid atherosclerosis had a more extensive cerebral collateral circulation 
and a slightly better median mRS at 90 days than patients with cardioembolic stroke.   (Stroke. 2019;50:3360-3368. 
DOI: 10.1161/STROKEAHA.119.026299.)
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In patients with ischemic stroke caused by an occlusion 
of a proximal intracranial artery treated with EVT, higher 
collateral scores are associated with a greater chance of a 
better functional outcome,4–6 presumably because intracra-
nial (leptomeningeal and pial) collateral arteries contribute to 
prolonged preservation of ischemic brain tissue at risk of in-
farction.7,8 Experimental studies in an animal model of bilat-
eral common carotid artery occlusion have found that chronic 
cerebral hypoperfusion promotes formation of new and re-
cruitment of existing intracranial collateral arteries.9 Cervical 
carotid atherosclerosis in humans develops over decades and 
is often accompanied by arterial stenosis. Theoretically, this 
might promote the cerebral collateral circulation. In contrast, 
since cardioembolic stroke is not accompanied by chronic ce-
rebral hypoperfusion, collateral artery formation and recruit-
ment are less likely in these patients.
We hypothesized that patients with ischemic stroke due to 
cervical stenotic carotid atherosclerosis have a more extensive 
collateral circulation than patients with stroke due to cardio-
embolism. We explored this hypothesis in a large sample of 
patients who underwent EVT for acute ischemic stroke with 
large vessel occlusion (LVO). We further assessed whether the 
presumed cause of stroke was associated with clinical, radio-
logical, and procedural outcomes after EVT.
Methods
Data will not be made available to other researchers, as no patient 
approval was obtained for sharing coded data. However, syntax and 
output files of statistical analyses may be made available on request.
Patient Selection
We used data of the MR-CLEAN Registry (Multicenter Randomized 
Controlled Trial of Endovascular Treatment for Acute Ischemic 
Stroke in the Netherlands), a prospective, nationwide registry of con-
secutive stroke patients treated with EVT in the Netherlands. For the 
current study, data of patients who underwent EVT between March 
16, 2014, and June 15, 2016, were used. We included adult patients 
with an LVO of the anterior circulation (internal carotid artery/in-
ternal carotid artery terminus [ICA/ICA-T], middle cerebral artery 
[M1/M2], anterior cerebral artery [A1/A2]), confirmed by computed 
tomography angiography (CTA), who were treated in a MR-CLEAN 
trial hospital, and had a cervical carotid stenosis greater than 50% due 
to atherosclerosis, or a cardiac source of stroke. The study protocol 
has been evaluated by the medical ethics committee of the Erasmus 
University Medical Center in Rotterdam, and permission to carry 
out the study as a registry was granted. All imaging was assessed by 
an imaging core laboratory, whose members were blinded to clin-
ical findings, except for side of symptoms. Detailed methods of the 
MR-CLEAN Registry have been reported previously.10
Stroke Etiology Assessment
All patients underwent CTA of the cervical arteries and 12-lead electrocar-
diography. Additional etiologic work-up was performed according to local 
protocols. Stroke etiology was determined from information in discharge 
letters and from reports of the imaging core laboratory. We used a modi-
fication of the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) 
criteria11 to categorize etiology into cervical large-artery atherosclerosis, 
cardioembolism, stroke of other determined cause, or undetermined cause 
(2 or more causes identified, negative, or incomplete evaluation). A patient 
was considered to have stroke due to cervical carotid atherosclerosis if 
there was >50% atherosclerotic stenosis or occlusion at the bifurcation of 
the carotid artery on the symptomatic side, as confirmed by core lab adju-
dication. Patients with high- or medium-risk cardioembolic stroke sources 
were classified as having cardioembolic stroke.11
Assessment of Collateral Circulation, 
Outcomes, and Thrombus Perviousness
Our primary outcome was collateral score, graded on baseline CTA by 
the imaging core laboratory on a 4-point scale, with 0 for absent collat-
erals (0% filling of the occluded vascular territory), 1 for poor (>0% and 
≤50% filling), 2 for moderate (>50% and <100% filling), and 3 for good 
collaterals (100% filling), as used previously.5,6,12 We also dichotomized 
the collateral scores into poor (grade 0–1) versus good (grade 2–3).
Clinical outcomes were the difference between National Institutes 
of Health Stroke Scale (NIHSS) score at baseline and at 24 to 48 
hours (ΔNIHSS); modified Rankin Scale (mRS) score at 90 days; 
functional independence at 90 days (defined as an mRS score of 
0–2); mortality at 90 days; and symptomatic intracranial hemorrhage. 
Intracranial hemorrhage was considered symptomatic if patients died 
or deteriorated neurologically (a decline of at least 4 points on the 
NIHSS), and the hemorrhage was related to the clinical deterioration 
(according to the Heidelberg criteria13).
Radiological outcomes were the proportion of patients with an 
extended Thrombolysis in Cerebral Infarction (eTICI) score of ≥2B 
and ≥2C.14 Procedural outcomes were the number of passes with a 
stent retriever; first-pass effect,15 defined as single pass/use of the de-
vice as first line of EVT, resulting in complete reperfusion (eTICI 3) 
of the LVO and its downstream territory and no use of rescue therapy 
after use of the device; and EVT procedure duration from groin punc-
ture to successful reperfusion (eTICI ≥2B) or last contrast bolus 
(when successful reperfusion was not achieved or no target occlusion 
was observed during the intervention).
To explore differences in thrombus imaging characteristics be-
tween cervical carotid atherosclerosis patients and patients with 
cardioembolism, we compared thrombus perviousness on baseline 
CTA. Thrombus perviousness is an imaging biomarker that estimates 
the extent to which a thrombus allows flow through the thrombus. 
This is measured as the thrombus attenuation increase (TAI or ∆) in 
Hounsfield units in the thrombus on CTA compared to noncontrast 
CT (∆=ρthrombusCTA−ρthrombusNCCT).16
Statistical Analysis
For the main analysis, we compared patients with cervical carotid 
atherosclerosis to patients with cardioembolic stroke. In line with 
an analysis previously performed in the NASCET (North American 
Symptomatic Carotid Endarterectomy Trial) in a nonacute ischemic 
stroke population with carotid artery stenosis,17 in a sensitivity anal-
ysis we compared collateral status and clinical outcomes of patients 
with moderate (51%–70%) to those with severe (71%–99%) stenosis 
within the sample of patients with cervical carotid atherosclerosis. 
Last, we analyzed clinical outcome between patients with cervical 
carotid atherosclerosis and cardioembolic stroke patients, within the 
sample of patients with incomplete reperfusion (eTICI 0–2A), since 
these patients would theoretically be most reliant on their collateral 
flow for preserving penumbral tissue.
Baseline characteristics were described using standard statis-
tics. The shift on the full mRS, measured with a common odds ratio 
(cOR), was estimated with ordinal logistic regression. We performed 
binary logistic regression for dichotomous outcome measures and 
linear regression for continuous outcome measures. Variables for 
adjustment were chosen based on theoretical identification using 
directed acyclic graphs.18 For associations with collateral status, we 
adjusted for age, history of stroke, and occlusion location. For clinical 
outcomes (∆NIHSS, mRS, functional independence, and mortality), 
we adjusted for age, history of peripheral artery disease, history of 
myocardial infarction, prior use of anticoagulant medication (vitamin 
K antagonists or direct oral anticoagulants), occlusion location, 
onset-to-groin-puncture time and hyperdense artery sign. For symp-
tomatic intracranial hemorrhage, we adjusted for history of myocar-
dial infarction. For successful reperfusion and procedural outcomes, 
we adjusted for age and occlusion location.
Missing data were imputed using multiple imputation based on 
relevant covariates and outcome. Adjusted (a)ORs and betas (β) 
are reported with 95% CI, and all P values are 2-sided. Statistical 
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analyses were performed using IBM SPSS Statistics for Windows, 
version 24.0.
Results
Of the 1627 patients in the MR-CLEAN Registry, 198 were 
excluded because of age under 18 years, posterior circulation 
occlusion, treatment in a non–MR-CLEAN trial hospital or 
because their discharge letter was not available to determine 
stroke etiology (Figure 1). Of the remaining 1429 patients, 
190 (13%) had cervical carotid atherosclerosis, and 476 (33%) 
had cardioembolism. Among the patients with cardioembo-
lism, 362 (76%) had atrial fibrillation (newly diagnosed in 
111). Other causes of cardioembolic stroke are listed in Table 
I in the online-only Data Supplement. Stroke of other deter-
mined etiology occurred in 67 (5%) patients, of whom 44 had 
carotid artery dissection. In 696 (49%) patients, the cause was 
undetermined; 78 had more than one potential cause and in 
618 the assessment was negative or incomplete.
Patients with cervical carotid atherosclerosis were 
younger (median 69 versus 76 years, P<0.001) and more 
often male (127/190 [67%] versus 223/476 [47%], P<0.001); 
had lower prestroke mRS scores (mRS score of 0–2, 180/187 
[96%] versus 399/471 [85%], P<0.001), and more often had 
an ICA/ICA-T occlusion (93/190 [49%] versus 87/450 [19%], 
P<0.001), than patients with cardioembolic stroke; Table 1.
We found a significant shift towards better collateral 
scores in favor of stroke due to cervical carotid atheroscle-
rosis (adjusted common odds ratio, 1.67 [95% CI, 1.17–2.39]; 
Figure 2). Also when scores were dichotomized into good 
(grade 2–3) and poor (grade 0–1), patients with cervical ca-
rotid atherosclerosis had significantly more often good col-
lateral scores than those with cardioembolic stroke (130/184 
[71%] versus 266/441 [60%], aOR, 1.84 [95% CI, 1.15–2.94]).
Patients with cervical carotid atherosclerotic stroke had 
a lower median mRS at 90 days than cardioembolic stroke 
patients (3 versus 4, adjusted common odds ratio, 1.45 [95% 
CI, 1.03–2.05]; Table 2). There were no statistically signifi-
cant differences in the proportions of patients with mRS score 
of 0–2 (46% versus 35%, aOR, 1.36 [95% CI, 0.90–2.07]) 
or mortality (23% versus 33%, aOR, 0.80 [95% CI, 0.48–
1.34]) at 90 days between cervical carotid atherosclerotic and 
cardioembolic stroke. In patients with cervical carotid ath-
erosclerosis a first-pass effect was achieved less frequently 
(10% versus 21%, aOR, 0.43 [95% CI, 0.23–0.80]), and me-
dian procedure duration was longer (73 versus 60 minutes, 
adjusted β=10.08 [95% CI, 4.64–16.96]) compared to patients 
with stroke because of cardioembolism. There were no sig-
nificant differences in any of the other clinical or radiological 
outcomes. Among the 82 patients with cervical carotid ather-
osclerosis who had a 51% to 99% stenosis, a slightly larger 
proportion of patients with a severe (71%–99%) stenosis had 
a good (grade 2–3) collateral status compared with those with 
a moderate (51%–70%) stenosis (75% versus 67%, P=0.423), 
but this difference disappeared after adjustment for confound-
ers (aOR, 1.06 [95% CI, 0.39–2.90]). A larger proportion of 
patients with a severe stenosis had mRS score of 0–2 at 90 
days, although this difference was not statistically significant 
(62% versus 41%, aOR, 1.66 [95% CI, 0.49–5.57]). Finally, in 
299 patients with incomplete reperfusion, functional outcome 
at 90 days was better for patients with cervical carotid athero-
sclerosis than for cardioembolic stroke patients (median mRS 
score of 4 versus 5, adjusted common odds ratio, 2.12 [95% CI, 
1.17–3.83]; Tables II through V and Figure I in the online-only 
Data Supplement).
Discussion
In line with our hypothesis, we found that patients who un-
derwent EVT for anterior circulation LVO caused by cervical 
large-artery atherosclerosis had a more extensive cerebral col-
lateral circulation and a better functional outcome at 90 days 
than those with cardioembolic stroke. We found no statisti-
cally significant difference in functional independence (mRS 
score of 0–2) or mortality between the groups.
The association between cervical large-artery ather-
osclerosis and better collateral circulation compared with 
cardioembolic stroke has been suggested previously in 2 
small cohort studies (N=15819 and 12220, respectively). 
However, both studies did not provide analyses adjusted for 
confounders for this association, which limits the interpre-
tation of the results. In addition, one of these studies20 only 
examined patients with atrial fibrillation and did not include 
other cardioembolic sources of stroke. Furthermore, our 
Figure 1. Flowchart of patient selection. 
Patients with cervical carotid atherosclerotic 
and cardioembolic stroke cause were included 
in the study. EVT indicates endovascular treat-
ment; and MR CLEAN Registry, Multicenter 
Randomized Controlled Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the 
Netherlands.
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study differs from these studies in terms of patient popula-
tion (proportion of patients with LVO) and use of a different 
collateral grading scale.
In our study, patients with cervical carotid atheroscle-
rotic stroke were younger and more often male than patients 
with cardioembolic stroke, which is consistent with previous 
Table 1. Baseline Characteristics
Cervical Carotid 
Atherosclerosis (N=190) Cardioembolism (N=476) P Value
Median age, y (IQR) 69 (62–77) 76 (66–83) <0.001
Men, n (%) 127/190 (67) 223/476 (47) <0.001
Medical history
  Diabetes mellitus, n/N (%) 27/186 (15) 89/474 (19) 0.196
  Hypertension, n/N (%) 83/187 (44) 290/473 (61) <0.001
  Ischemic stroke, n/N (%) 25/187 (13) 89/475 (19) 0.10
Medication
  DOAC, n/N (%) 0/186 (0) 27/465 (6) 0.001
  Vitamin K antagonist, n/N (%) 4/190 (2) 150/471 (32) <0.001
  Antiplatelets, n/N (%) 63/189 (33) 146/468 (31) 0.594
  IV r-tPA before EVT, n (%) 166/190 (87) 291/476 (61) <0.001
Prestroke mRS, n/N (%) <0.001
  0 147/187 (79) 282/471 (60)  
  1 23/187 (12) 77/471 (16)  
  2 10/187 (5) 40/471 (9)  
  ≥3 7/187 (4) 72/471 (12)  
Clinical characteristics
  Median NIHSS (IQR)* 16 (12–19) 16 (12–20) 0.358
  Median systolic blood pressure, mm Hg (IQR)† 156 (142–170) 150 (131–167) 0.003
  Median diastolic blood pressure, mm Hg (IQR)‡ 80 (71–90) 80 (70–93) 0.806
  Median onset-to-groin in minutes (IQR) 207 (165–270) 210 (160–270) 0.962
Laboratory investigations
  Median serum glucose (IQR)§ 6.5 (5.8–7.8) 6.8 (6–8.1) 0.095
  Median platelet count (IQR)‖ 235 (208–281) 231 (187–587) 0.232
  Median INR (IQR)¶ 1 (1–1) 1 (1–1.5) <0.001
Imaging characteristics
  Median ASPECTS (IQR)# 8 (7–10) 9 (7–10) 0.158
  Occlusion location on CT angiography, n/N (%) <0.001
  ICA 30/190 (16) 6/450 (1)  
  ICA-T 63/190 (33) 81/450 (18)  
  Proximal M1 53/190 (28) 119/450 (26)  
  Distal M1 36/190 (19) 171/450 (38)  
  M2 8/190 (4) 68/450 (1)  
  Hyperdense artery sign, n/N (%) 128/183 (70) 229/450 (51) <0.001
  Median TAI in Hounsfield units (IQR)** 6.9 (1.7–15.7) 3.9 (1.6–11.1) 0.068
  Clot length, mm (IQR)†† 20.5 (14.2–28.3) 12.3 (9.0–16.5) <0.001
ASPECTS indicates Alberta Stroke Program Early CT Score; DOAC, direct oral anticoagulant; EVT, endovascular treatment; ICA, internal 
carotid artery; ICA(-T), internal carotid artery (terminus); INR, international normalized ratio; IQR, interquartile range; IV r-tPA, intravenous 
recombinant tissue-type plasminogen activator; M1, first segment of middle cerebral artery; M2, second segment of middle cerebral 
artery; mRS, modified Rankin Scale score; NIHSS, National Institutes of Health Stroke Scale; and TAI, thrombus attenuation increase (∆).
Number of patients with missing data for cervical carotid atherosclerosis and cardioembolism group, respectively: *3,7; †2,10; ‡2,15; 
§24,65; ‖23,64; ¶31,75; #5,20; **145,350; and ††145,350.
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studies.21 Prestroke mRS scores were lower in cervical ca-
rotid atherosclerosis patients, possibly, in part, due to younger 
age and less comorbidity. Patients with cervical carotid ath-
erosclerotic stroke received IV r-tPA (intravenous recombi-
nant tissue-type plasminogen activator) more frequently than 
patients with cardioembolic stroke, which is explained by oral 
anticoagulation use in the latter group. Notably, there was no 
difference in baseline NIHSS score between cervical carotid 
atherosclerotic and cardioembolic stroke patients. In studies 
using data of non-EVT populations, cardioembolic stroke is 
generally reported to present with more severe deficits than 
stroke of other origins.1,2 This is explained by the fact that car-
dioembolic stroke is usually associated with relatively large 
thrombi resulting more often in LVO compared with stroke 
of other etiology.22 As our study population consisted solely 
of patients with a LVO, this likely explains why we did not 
observe a difference in severity of deficits between cervical 
large-artery atherosclerosis and cardioembolic stroke. In fact, 
in our study, we found a higher occurrence of intracranial in-
ternal carotid artery and terminal internal carotid artery occlu-
sions in patients with cervical large-artery atherosclerosis, 
similar to a distribution previously found in a study comparing 
these 2 groups who underwent EVT.20
The association between collateral status and 90-day mRS 
scores and mortality is well established in EVT patients.4,5 In 
line with these observations, we found a small statistically sig-
nificant difference in median mRS in favor of patients with 
cervical carotid atherosclerosis. However, this result should be 
interpreted with caution because there was no statistically sig-
nificant difference in functional independence nor in mortality 
and the difference in mRS only just reached statistical signif-
icance. Similarly, a MR-CLEAN subgroup analysis compar-
ing EVT patients with and without atrial fibrillation found no 
significant differences in outcome.23 In further support of our 
hypothesis, when only selecting those patients with incom-
plete reperfusion (eTICI 0–2A), patients with carotid ather-
osclerosis did have a better functional outcome than patients 
with cardioembolism. This may suggest that in patients who 
are truly dependent on their collaterals, patients with cervical 
carotid atherosclerosis have a small benefit. However, despite 
adjusting for potential confounders, several baseline imbal-
ances remained in this subgroup analysis (ie, eTICI 0–2A 
patients with cardioembolism more often had a worse pre-
stroke mRS, a medical history of ischemic stroke and hyper-
tension, and less often received IV r-tPA) and we, therefore, 
cannot rule out residual confounding. We must also emphasize 
Figure 2. Collateral circulation for patients with 
stroke due to cervical carotid atherosclerosis vs 
stroke due to cardioembolism. Collateral score 
was graded by the imaging core laboratory on a 
4-point scale, with 0 for absent (0% filling of the 
occluded vascular territory), 1 for poor (>0% and 
≤50% filling), 2 for moderate (>50% and <100% 
filling), and 3 for good collaterals (100% filling).
Table 2. Clinical, Radiological, and Procedural Outcomes
Cervical Carotid 
Atherosclerosis (N=190) Cardioembolism (N=476)
Adjusted (Common) OR/β 
(95% CI)
Clinical outcomes
  Median ΔNIHSS (IQR)* 4 (0–9) 3 (0–9) 0.51 (−0.99–2.00)
  Median mRS at 90 d (IQR)† 3 (1–5) 4 (2–6) 1.45 (1.03–2.05)
  mRS score of 0–2 at 90 d, n/N (%) 80/175 (46) 150/431 (35) 1.36 (0.90–2.07)
  Mortality, n/N (%) 40/175 (23) 142/431 (33) 0.80 (0.48–1.34)
  Symptomatic intracranial hemorrhage, n/N (%)‡ 13/190 (7) 22/476 (5) 1.42 (0.70–2.85)
Radiological outcomes, n/N (%)
  Post-EVT eTICI score ≥2B 96/186 (52) 261/470 (56) 0.85 (0.59–1.22)
  Post-EVT eTICI score ≥2C 66/186 (36) 188/470 (40) 0.77 (0.51–1.14)
Procedural outcomes
  First-pass effect,§ n/N (%) 14/135 (10) 76/367 (21) 0.43 (0.23–0.80)
  Median number of passes with stent retriever (IQR)§,‖ 2 (1–3) 2 (1–3) 0.21 (−0.62–1.03)
  Median procedure duration in minutes (IQR)¶ 73 (50–102) 60 (40–90) 10.08 (4.64–16.96)
eTICI indicates extended Treatment in Cerebral Ischemia; EVT, endovascular treatment; IQR, interquartile range; mRS, modified Rankin Scale score; 
NIHSS, National Institutes of Health Stroke Scale; and OR, odds ratio.
Number of patients with missing data for cervical carotid atherosclerosis and cardioembolism group, respectively: *23,51; †15,45; ‖55,108; and ¶33,43.
‡Heidelberg criteria, von Kummer et al,13 Stroke.
§In patients with at least one attempt at thrombectomy with a device.
¶Femoral artery puncture to successful recanalization (eTICI ≥2B) or last contrast bolus (when successful recanalization was not achieved or no target 
occlusion was observed during the intervention).
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the explorative nature of this analysis. Finally, our study and 
its subgroup analyses may be underpowered to detect a true 
difference.
However, collateral status may not be the main deciding 
factor when studying the association between stroke etiology 
and outcome. For one, the procedural outcomes in both groups, 
which were in favor of cardioembolic stroke patients, may in 
part explain the lack of significant differences in clinical and 
radiological outcomes. Patients with cervical carotid athero-
sclerotic stroke had longer procedure duration than patients 
with cardioembolic stroke, which could reflect difficulties in 
gaining intracranial access (eg, due to cervical stenosis) or 
performance of percutaneous transluminal angioplasty. Also, 
in patients with cervical carotid atherosclerosis, eTICI 3 on 
first pass was achieved less often. Perhaps this is due to differ-
ences in thrombus length. Patients with cervical carotid ather-
osclerosis more often had ICA/ICA-T occlusions, and longer/
larger thrombi are more difficult to remove in one attempt.15 
Thrombus composition may also be a factor in achieving first-
pass effect.24,25 Although we do not have histological data on 
thrombus composition, in our study we found that patients 
with cervical carotid atherosclerosis more often had a hyper-
dense artery sign, but there was no statistically significant dif-
ference in thrombus perviousness between the 2 groups.
Our study has several limitations. First, a large group of 
patients had an undetermined stroke etiology (49% compared 
with ≈25% in most studies).26 The higher proportion of patients 
with stroke of undetermined etiology is partially explained by 
the absence of patients with small vessel disease in a cohort 
of patients treated with EVT. Undetermined cause (excluding 
those with more than one possible cause) can be the result 
of negative evaluation or of incomplete evaluation. The ma-
jority of the patients with cardioembolic stroke etiology in our 
study had atrial fibrillation. Atrial fibrillation generally only 
accounts for about half of all cardioembolic causes.27 Atrial 
fibrillation may be relatively more prevalent than other car-
dioembolic sources in patients with LVO. Alternatively, the 
work-up for other cardioembolic sources may have been in-
complete,28 and a proportion of patients with undetermined eti-
ology may have had a cardioembolic source.26 Unfortunately, 
detailed data on electrocardiography, rhythm monitoring, and 
echocardiography were unavailable for some patients, which 
is a result of a registry of daily clinical practice.
A second limitation is that all patients underwent single-
phase CTA instead of multiphase CTA, which could have led 
to underestimation of collateral status in the case of delayed 
filling in combination with an early acquisition phase.29,30 This 
underestimation may disproportionally affect patients with 
occlusion due to cervical large-artery atherosclerosis, who 
more often had ICA-T occlusions than patients with cardioem-
bolism, which may lead to slower or less contrast flow in ante-
rior and middle cerebral artery territories. Still, if this were the 
case, the true difference in collateral status between patients 
with cervical large-artery atherosclerosis and cardioembolic 
stroke would be even more pronounced. Furthermore, cur-
rent methods for collateral circulation assessment on CTA are 
rather coarse. Conventional digital subtraction angiography is 
generally considered the golden standard.8 More quantitative 
CTA scores have the potential to be more discriminative.31
Third, important considerations when studying stroke eti-
ology, collateral circulation and outcomes, are thrombus size 
and thrombus composition.32 Smaller thrombi may allow for 
increased pial collateral flow, increasing collateral score.33 In 
patients with larger clots, this might have led to underestima-
tion of collateral circulation. Although we did not analyze 
thrombus histopathology, we did have thrombus perviousness 
at our disposal. If cervical large-artery atherosclerotic thrombi 
are more pervious than cardioembolic thrombi, this would 
allow for better vessel opacification in stroke due to cervical 
large-artery atherosclerosis, leading to an overestimation of 
the difference in collateral score between the 2 groups. In our 
study, we did not find a statistical difference in TAI between 
cervical large-artery atherosclerotic and cardioembolic stroke.
Conclusions
In patients who underwent EVT because of LVO of the ante-
rior circulation, stroke due to cervical carotid atherosclerosis 
was associated with better collateral status and a slightly bet-
ter functional outcome at 90 days compared to cardioembolic 
stroke. However, there was no statistically significant differ-
ence in functional independence nor in mortality between 
patients with cervical carotid atherosclerotic stroke and those 
with cardioembolic stroke. This discrepancy may be partially 
explained by better procedural outcomes in cardioembolic 
stroke patients.
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